Search Results
Your search for can matches 13758 pages
Showing 13651 - 13700ASCO 2013: 10 Years of Tamoxifen Better Than 5 in Reducing Breast Cancer Recurrence and Death
Ten years of adjuvant treatment with tamoxifen reduces breast cancer recurrence and mortality among women treated for early-stage estrogen receptor (ER)–positive breast cancer, according to results of the British phase III aTTom study. These findings, presented at the 2013 ASCO Annual Meeting ...
ASCO 2013: Sorafenib Stalls Growth of Treatment-resistant Differentiated Thyroid Cancer
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer
Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...
ASCO 2013: Adding GM-CSF to Ipilimumab Significantly Improves Survival for Patients with Metastatic Melanoma
Adding granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine) to ipilimumab (Yervoy) at a 10 mg/kg dose significantly improved survival compared to the same dose of ipilimumab alone, according to results of a proof-of-principle phase II trial. One year after the start of therapy,...
ASCO 2013: Most U.S. Oncologists Report High Career Satisfaction, but Many Suffer Symptoms of Burnout
Although a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, according to a Mayo Clinic–led study released during the ASCO 2013 Annual Meeting (Abstract 6533). “Oncology can be a tremendously rewarding...
ASCO 2013: Pazopanib Maintenance Therapy Delays Relapse of Advanced Ovarian Cancer
A phase III clinical trial has found that pazopanib (Votrient), an oral multikinase inhibitor, extends disease-free survival by an average of 5.6 months, compared to placebo, in women with advanced ovarian cancer who had initial successful treatment with surgery and chemotherapy. “Our...
Experts Call for Breast Cancer Trials Aimed at Younger Patients
A lack of clinical trials aimed specifically at younger patients with breast cancer could be partly to blame for their poor survival rates, according to a study published in the Journal of the National Cancer Institute. Study Details The study analyzed 2,956 women diagnosed with breast cancer...
New Possibilities for Prostate Cancer Treatment
An Australian study has identified a subgroup of prostate cancer cells that survive androgen deprivation therapy and could contribute to prostate cancer recurrence. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development,...
Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow. In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling,...
EGFR Prevents Maturation of Cancer-fighting microRNAs under Hypoxia
Under conditions of oxygen starvation often encountered by tumors, the epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood, the...
Phase II Trial Targeting Genetic Anomaly in Castration-resistant Metastatic Prostate Cancer Underway
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Physicians have more information to share with their patients about the benefits and risks of low-dose computed tomography (CT) lung cancer screening following the publication in the New England Journal of Medicine of the results of the first (of three planned) annual screening examinations from...
Genetic Diversity Predicts Outcomes in Head and Neck Cancer
A new measure of the heterogeneity of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear...
Study: Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current...
Molecular Marker from Pancreatic 'Juices' Helps Identify Pancreatic Cancer
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
ASCO 2013: Routine Surveillance Imaging Scans Add Little to Detection of Relapse in Patients with Diffuse Large B-cell Lymphoma
A large study reports that the vast majority of diffuse large B-cell lymphoma relapses are detected based on symptoms, abnormal blood tests or abnormal findings on physical exam, suggesting that CT scans, which are currently a routine part of follow-up, may be unnecessary. Researchers found that...
ASCO 2013: Surveillance Following Surgery Is Sufficient for Men with Stage I Seminoma
A long-term study of men with stage I seminoma, a common form of testicular cancer, suggests that surveillance for cancer recurrence, rather than additional chemotherapy or radiation therapy, is sufficient for the vast majority of men who have undergone successful surgery for their cancer....
ASCO 2013: New Drug Targeting PI3K-delta Shows Strong Activity in Early Trial for High-risk Chronic Lymphocytic Leukemia
Results from a phase I study of a new oral targeted drug, idelalisib (GS-1101), show the agent has potential as a therapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL). The drug produced rapid and long-lasting tumor shrinkage in half of the patients treated with...
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
ASCO 2013: Standard-dose Radiation Is Superior to High-dose Radiation for Patients with Locally Advanced Stage III NSCLC Undergoing Chemotherapy
A phase III trial in patients with stage III non–small cell lung cancer (NSCLC) concluded that standard-dose radiotherapy (60 Gy) is safer and more effective than high-dose radiotherapy (74 Gy), extending survival by 9 months and causing fewer treatment-related deaths. While 60 Gy is already...
ASCO 2013: Anti–PD-L1 Drug Shows Promising Anticancer Effects in a Variety of Advanced Cancers
A phase I expansion study of the investigational drug MPDL3280A— an engineered PD-L1 targeted antibody—shows impressive tumor shrinkage rates in patients with several different cancers—including lung, melanoma, kidney, colorectal, and gastric cancers—that had progressed...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
Dual Targeting of Metastatic Breast Cancer Improves Survival Rates
A new study from the USC Norris Comprehensive Cancer Center showed that targeting both hormone receptors and human epidermal growth factor receptor 2 (HER2) in first-line treatment of patients with metastatic breast cancer significantly increased overall survival times. A team of researchers led...
Study Establishes Basis for Genomic Classification of Endometrial Cancers
A comprehensive genomic analysis of nearly 400 endometrial tumors suggests that certain molecular characteristics, such as the frequency of mutations, could complement current pathology methods and help distinguish between principal types of endometrial tumors, as well as provide insights into...
Blocking a Single Gene Renders Tumors Less Aggressive, Johns Hopkins Researchers Find
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called “master regulator” gene may be the key to...
Emil ‘Tom’ Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
Radiation Therapy May Be Unnecessary for Postmenopausal Patients with Early-stage Breast Cancer after Conservative Surgery
Postmenopausal women aged 55 to 75 with early-stage breast cancer can be safely treated with breast-conserving surgery without postoperative radiation therapy, according to a double-arm, prospective, randomized study presented this week at the American Society of Breast Surgeons Annual Meeting. The ...
Selective Estrogen Receptor Modulators Reduce Breast Cancer Rates by More Than a Third in Women at High Risk
Tamoxifen and three similar drugs reduce breast cancer incidence by 38% in women at an increased risk of the disease according to a Cancer Research UK study published in The Lancet today. In the most comprehensive study to date scientists calculate that one breast cancer would be prevented for...
Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center (URMC) team has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast...
Delays in Diagnosis Worsen Outlook for Minority, Uninsured Pediatric Retinoblastoma Patients, Study Finds
When retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other children, probably because of delays in diagnosis, researchers at Dana-Farber/Children's...
Majority of Children Readmitted to Hospital Following Stem Cell Transplant
Nearly two-thirds of children receiving stem cell transplants returned to the hospital within 6 months for treatment of unexplained fevers, infections, or other problems, according to a study performed at Dana-Farber/Children’s Hospital Cancer Center in Boston. Children who received donor...
New Agent Might Control Breast Cancer Growth and Spread
A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) suggests that an unusual experimental drug can reduce breast cancer aggressiveness, reverse resistance to...
Study to Treat Deadly Form of Thyroid Cancer Shows Promise, Mayo Clinic Says
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, said researchers at Mayo Clinic in Florida. Anaplastic thyroid cancer is one of the deadliest of all cancers. Nearly all patients diagnosed...
Pharmacyclics Completes Enrollment of Phase III Ibrutinib CLL Study and Phase II Ibrutinib MCL Study
Pharmacyclics, Inc, announced today that the enrollment target of 350 patients for RESONATE, its phase III study using ibrutinib monotherapy vs ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, was achieved on April 3, 2013. As...
New Labeling for Reformulated OxyContin to Curb Abuse
The U.S. Food and Drug Administration has approved updated labeling for the reformulated painkiller OxyContin (controlled-release oxycodone hydrochloride). The new labeling will indicate that the drug has physical and chemical properties that make injection or snorting challenging. This new measure ...
The U.S. Supreme Court Hears Arguments Challenging Patents on Breast and Ovarian Cancer Genes
The U.S. Supreme Court heard arguments Monday in a case seeking to invalidate patents on two genes associated with hereditary breast and ovarian cancer. The American College of Medical Genetics and Genomics (ACMG) was one of the first plaintiffs to sign onto this historic legal case. ACMG was also ...
Cryoablation Spot Treats Cancer in the Lung, Extends Survival
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results were presented on April 14, 2013, at the Society of Interventional Radiology’s 38th Annual Scientific Meeting in New Orleans....
Mammogram Tool Improves Some Breast Cancer Detection but Also Increases False Alarms
A costly and widely used mammography add-on increases detection of noninvasive and early-stage invasive breast cancer but also makes more mistakes than mammography alone, researchers from UC Davis and the University of Washington have found. A new study shows that computer-assisted detection (CAD) ...
Key Bone Marrow Protein Identified as Potential New Leukemia Treatment Target
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with...
NIH Trial Shows Promising Results in Treating Primary Mediastinal B-cell Lymphoma
Patients with primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to the mediastinum, had excellent outcomes, according to clinical trial results. Until now, most standard treatment approaches for patients with this type of...
Adding Cetuximab to Chemotherapy Enables Select Patients with Advanced Colorectal Cancer and Liver Metastasis to Undergo Surgery
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed. Such surgery can be curative, and is...
Novel Two-step Immunotherapy Showed Promise for Patients with Recurrent Ovarian Cancer
A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, DC,...
Biomarker Analysis Identified Women Most Likely to Benefit from T-DM1
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from T-DMI—also now known as ado-trastuzumab emtansine (Kadcyla)—according to data from a subanalysis of the phase III clinical trial that led the FDA to...
Statement by ASCO President Sandra M. Swain, MD, FACP, in Support of the Rally for Medical Research, April 8, 2013
A strong, stable federal investment in cancer research, prevention, and treatment is critical to continue the progress we are making for the more than 1.66 million Americans newly diagnosed with cancer every year. ASCO calls on Congress to renew its commitment to this life-sustaining research. As...
Leading Health-care Organizations Issue Guideline Recommendations for Molecular Testing and Targeted Therapies
The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number 1 cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK...
For the First Time, Researchers Isolate Adult Stem Cells from Human Intestinal Tissue
For the first time, researchers at the University of North Carolina at Chapel Hill have isolated adult stem cells from human intestinal tissue. The accomplishment provides a much-needed resource for scientists eager to uncover the true mechanisms of human stem cell biology. It also enables them to ...
Antidepressant Helps Relieve Pain from Chemotherapy, Study Finds
The antidepressant drug duloxetine (Cymbalta) helped relieve painful numbness and tingling feelings caused by chemotherapy in 59% of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain. Chemotherapy-induced peripheral neuropathy is a common...
New Diagnostic Technology May Lead to Individualized Treatments for Prostate Cancer
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, has enhanced a device they developed to identify and “grab” circulating tumor cells (CTCs) that break away from cancers and enter the blood, often leading to the...
